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Abstract
Background: The endozepine triakontatetraneuropeptide (TTN) induces intracellular calcium
([Ca++]i) changes followed by activation in human polymorphonuclear leukocytes (PMNs). The
present study was undertaken to investigate the role of protein kinase (PK) C in the modulation of
the response to TTN by human PMNs, and to examine the pharmacology of TTN-induced Ca++
entry through the plasma membrane of these cells.
Results:  The PKC activator 12-O-tetradecanoylphorbol-13-acetate (PMA) concentration-
dependently inhibited TTN-induced [Ca++]i rise, and this effect was reverted by the PKC inhibitors
rottlerin (partially) and Ro 32-0432 (completely). PMA also inhibited TTN-induced IL-8 mRNA
expression. In the absence of PMA, however, rottlerin (but not Ro 32-0432) per se partially
inhibited TTN-induced [Ca++]i rise. The response of [Ca++]i to TTN was also sensitive to mibefradil
and flunarizine (T-type Ca++-channel blockers), but not to nifedipine, verapamil (L-type) or ω-
conotoxin GVIA (N-type). In agreement with this observation, PCR analysis showed the expression
in human PMNs of the mRNA for all the α1 subunits of T-type Ca++ channels (namely, α1G, α1H,
and α1I).
Conclusions: In human PMNs TTN activates PKC-modulated pathways leading to Ca++ entry
possibly through T-type Ca++ channels.
Introduction
Triakontatetraneuropeptide [diazepam-binding inhibitor
(DBI) 17–50, TTN] is one of the major endogenous pep-
tides generated through the cleavege of DBI, a
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neuropeptide also known as acyl-CoA-binding protein
[1]. DBI and DBI-derived peptides are also called
endozepines, after the ability of at least some of them to
recognize the diazepam binding site on the GABAA recep-
tor, and are widely distributed in the CNS and in periph-
eral organs [2,3]. In particular, immune tissues express
DBI [4] and evidence exists that TTN and its related pep-
tides octadecaneuropeptide (DBI 33–50, ODN) and eik-
soneuropeptide (DBI 51–70, ENP) can affect the immune
response. In particular, TTN and ODN stimulate the pro-
duction of tumor necrosis factor (TNF) alpha, interleukin
(IL)-1 beta, IL-8, granulocyte/macrophage colony-stimu-
lating factor, IL-6 and IL-8 in human monocytes [5,6], and
ODN enhances the LPS-induced secretion of IL-6 in
human peripheral blood mononuclear cells [7].
In human polymorphonuclear leukocytes (PMNs) we pre-
viously showed that TTN rises intracellular calcium
([Ca++]i) and stimulates chemotaxis, O2
-  generation,
phagocytosis and IL-8 production [8,9]. Pharmacological
analysis of TTN-induced [Ca++]i changes and IL-8 produc-
tion suggested that these responses are brought about
through a pertussis toxin (PTX) sensitive, G protein-cou-
pled receptor linked to phospholipase C (PLC), which
once activated induces both Ca++ release from thapsi-
gargine-sensitive intracellular stores and Ca++ entry from
the extracellular space [9]. In those experiments, prelimi-
nary evidence also suggested the possible involvement of
protein kinase (PK) C, inasmuch as the PKC inhibitor cal-
phostin C significantly affected (although did not com-
pletely block) TTN-induced effects.
The present study was therefore undertaken to investigate
more in-depth, by use of a pharmacological approach, the
role of PKC in the modulation of the response to TTN by
human PMNs, and to better characterize TTN-induced
Ca++ entry through the plasma membrane by testing its
sensitivity to different Ca++-channel blockers. The results
show that the stimulatory effect of TTN is profoundly
affected by PKC activation, and suggest that different PKC
isoforms may play distinct roles. Evidence is also provided
that TTN-induced Ca++ entry is specifically sensitive to T-
type Ca++-channel blockers. The possibility that T-type
Ca++-channels may represent the target for the effects of
these drugs on human PMNs is further supported by the
observation that these cells express the mRNAs for T-type
Ca++-channel α1 subunits.
Materials and Methods
Drugs and chemicals
TTN was obtained from Neosystem SA (Strasbourg,
France); Bovine serum albumine (BSA), HEPES, EDTA,
EGTA, Trizma Base, 12-O-tetradecanoylphorbol-13-ace-
tate (PMA), 4α-phorbol-12,13-didecanoate (α-PMA), rot-
tlerin, Ro 32-0432 (hydrochloride), L-verapamil, ω-
conotoxin GVIA, flunarizine, and mibefradil (hydrochlo-
ride) were obtained from Sigma Aldrich (St. Louis, MO).
Fura-2/AM was obtained from Calbiochem-Novabio-
chem Corp. (La Jolla, CA). Dextran and Ficoll-Paque Plus
were obtained from Pharmacia Biotech (Uppsala, Swe-
den). All other reagents and solvents were from Merck
(Darmstadt, Germany). All solutions were daily freshly
preparated from stock solutions stored at -20°C until use.
Cell preparation
PMNs were isolated from venous blood obtained from
healthy volunteers using heparinized tubes. Whole blood
was allowed to sediment on dextran at 37°C for 30 min.
Supernatant was recovered and PMNs were isolated by
Ficoll-Paque Plus density-gradient centrifugation. Con-
taminating erythrocytes were eliminated by 10 min hypo-
tonic lysis in distilled water with added (g/l): NH4Cl
8.248, KHCO3 1.0, EDTA 0.037. Cells were then washed
three times in NaCl 0.15 M and resuspended in 1 ml Ca++/
Mg++-free PBS (composition as follows [g/l]: NaCl 8.000,
KCl 0.200, Na2HPO4xH2O 1.288, KH2PO4 0.200) with
added 0.25% BSA. Purity and viability of PMNs prepara-
tions were >95% and no platelets or erythrocytes could be
detected either by light microscopic examination or by
flow cytometric analysis.
Measurement of [Ca++]i
PMNs were resuspended at the concentration of 2 × 106/
ml and incubated at 37°C with 5 µM Fura-2/AM (stock
solution, 1 mM in dimethyl sulfoxide). After 30 min, cells
were washed thrice by gentle centrifugation (5 min, 300
g), resuspended in PBS supplemented with 10 mM
HEPES, 10 mM glucose, 0.25% BSA and 1 mM CaCl2 and
placed in a thermostatically controlled (37°C) cuvette
equipped with a cuvette stirrer for [Ca++]i measurement.
Fluorescence measurements were performed using a spec-
trofluorimeter (Perkin-Elmer LS-50B, Perkin Elmer Instru-
ments, Bridgeport, CT). Excitation of Fura-2 was
performed at 340 and 380 nm, with excitation band
widths set at 5 nm. The ratio of emitted fluorescence sig-
nals (510 nm) was used to calculate the cytosolic free Ca++
concentration according to Grynkiewicz et al. [10] and
calibration was performed by the addition of 0.5% Triton
X 100 and 1 mM CaCl2 (max) or 45 mM TRIS and 50 mM
EGTA/TRIS (min). In each experiment, [Ca++]i changes
were calculated as the difference (∆) between the highest
values (peak levels) reached after addition of the agent
and the mean 1-min pretreatment values (resting levels).
PCR analysis
Total RNA was extracted from 1 × 106 PMNs by Perfect
RNA Eukaryotic Mini kit (Eppendorf, Hamburg, Ger-
many). The kit utilizes a chaotropic guanidinium isothio-
cyanate solution for cell lysis and rapid inactivation of
cellular RNAses. RNA is subsequently bound to the matrixCell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/6
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of the column, washed to remove contaminants and then
eluted with molecular biology grade water. In the present
study, the amount of extracted RNA was estimated by
spectrophotometry at 260 nm. Total RNA was reverse
transcribed and cDNA was amplified using a one-step RT-
PCR reaction kit (Finnzymes, Espoo, Finland). Briefly, 1
µg total RNA was added to a reaction mixture consisting
of 5 µl RT-10x reaction buffer, 1 µl MgCl2 50 mM, 1 µl
deoxynucleotide triphosphate mixture (10 nM each), 1 µl
specific primer (Invitrogen, San Giuliano Milanese, MI,
Italy), 1 µl avian myeloblastosis virus RT 5 U/ml, 1 µl ther-
mostable DNA polymerase (DYNazyme™ II DNA
polymerase) 1 U/ml. Diethylpyrocarbonate-treated water
was added up to a final volume of 50 µl. PCR was then
brought about by using a thermocycler (GeneAmp PCR
System 2400, Perkin Elmer Instruments). For the analysis
of IL-8 mRNA, 30 cycles of PCR were performed according
to the following steps: 48°C, 30 min (once); 94°C, 30 s
65°C, 45 s and 72°C, 45 s. For the analysis of T-type Ca++-
channel α1 subunit mRNAs, 35 cycles of PCR were per-
formed according to the following steps: 45 min at 48°C,
then 30 s at 94°C, 30 s at 63°C, 1 min at 72°C, followed
by a 10 min-extension period at 72°C. At the end, the
reaction mixture was kept for 15 min at 72°C and finally
chilled at -4°C until analysis, which was performed on a
10 µl aliquot of the PCR product by electrophoretical sep-
aration on a 2% agarose gel and subsequent visualization
by ethidium bromide staining (BIORAD, Hercules, CA).
Quantification of the amount of RT-PCR products was
carried out by densitometric analysis of photographic neg-
atives of the agarose gel by use of a software for image
analysis (Multi-Analyst, BIORAD). For selection of the
primers, we referred to the National Center for Biotech-
nology Information http://www.ncbi.nlm.nih.gov/ data-
base and to published literature. Selected primers are
shown in Table 1. Data were finally presented as optical
density ratio (in arbitrary units), with respect to expres-
sion of the mRNA for the housekeeping gene (hypoxan-
thine-guanine phosphorybosyl transferase [HPRT] for IL-
8 and β-actin for T-type Ca++-channel α1 subunits).
Statistical analysis
Data are shown as means ± standard deviation (SD) of the
mean. Statistical significance of the differences among
groups was assessed by two-tailed Student's t test or by
ANOVA followed by Bonferroni post test for paired or
unpaired data, as appropriate. The concentration-
response relationship of PMA was analyzed by nonlinear
regression using a commercial software (Prism 2.0,
GraphPad Software Inc., San Diego, CA, USA) and a sig-
moidal concentration-response curve was fitted to find
the mean value of the EC50 (i.e., the concentration which
elicited 50% of the maximal response) together with its
95% confidence interval (C.I.).
Results
Effect of PKC ligands
In agreement with previous studies [8,9], in human PMNs
TTN 100 µM induced a rapid and transient rise of [Ca++]i
and increased the expression of IL-8 mRNA. The PKC acti-
vator PMA (but not its inactive analogue α-PMA) reduced
the effect of TTN 100 µM on [Ca++]i rise in a concentra-
tion-dependent fashion (Fig. 1). PMA also reduced TTN-
induced IL-8 mRNA expression (control: 0.44 ± 0.15; TTN
100 µM: 1.04 ± 0.23, P < 0.01 vs control; TTN + PMA 100
ng/ml: 0.28 ± 0.07, not significant vs control, P < 0.001 vs
TTN alone), while also in this regard α-PMA was com-
pletely ineffective (TTN + α-PMA 100 ng/ml: 0.82 ± 0.28,
P < 0.05 vs control, not significant vs TTN alone). The
mean EC50 value (with 95% C.I.) for PMA-induced reduc-
tion of TTN-induced [Ca++]i rise was 0.06 (0.05–0.07) ng/
ml. PMA however failed to completely abolish the effect
of TTN, which even in the presence of PMA 1–100 ng/ml
was able to evoke a slow and progressive rise of [Ca++]i
about 20% of that in the presence of TTN alone (Fig. 1).
The effect of PMA was concentration-dependently
Table 1: PCR primers used for the detection of IL-8 and of T-type Ca++-channel α1 subunits.
Primer sequence Annealing temperature PCR product Ref.
IL-8 5'-CCACCCATGGCAAATCCATGGC-3'
5'-TCTCAGCCCTCTTCAAAAACTTCTC-3'
65°C 289 [31]
α1G 5'-CCTGGACTTCTTCACGATGT-3'
5'-CCAGGTCTGCTGGGTCAGAG-3'
63°C 395 [32]
α1H 5'-TGTTCGTGACGGACTCGAATT-3'
5'-AGTGCACAGAGGCAACGGA-3'
63°C 436 [32]
α1I 5'-TTCCCCTACACCGGAACGG-3'
5'-TAGTAACGGTTCCAGTTGA-3'
50°C 227 [32]
HPRT 5'-CCTGCTGGATTACATTAAAGCACTG-3'
5'-CTTCGTGGGGTCCTTTTCACCAGC-3'
65°C 370 Genbank n. M26434
β-actin 5'-GGAAATAGGGGTTAGCAC-3'
5'-CTCATGTGCGCCTACTTA-3'
56°C 929 Genbank n. AJ005353Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/6
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reverted by 5-min preincubation with rottlerin 3–10 µM
and with Ro 32-0432 5–50 nM. However, the reversion
induced by Ro 32-0432 was complete, while that induced
by rottlerin was only partial (Table 2). In the absence of
PMA, rottlerin (but not Ro 32-0432) per se was also able
to inhibit TTN 100 µM-induced [Ca++]i rise in a concentra-
tion-dependent fashion (Fig. 2). The mean EC50 value
(with 95% C.I.) of rottlerin was 5.77 (3.91–8.51) µM.
PMA, α-PMA, Ro 32-0432, and rottlerin at the concentra-
tions used had per se no significant effect on the parame-
ters under study (data not shown).
Effect of Ca++ channel blockers and evidence for the 
presence of T-type Ca++ channels in human PMNs
Preincubation for 5 min with the chemically unrelated T-
type Ca++  channel blockers flunarizine or mibefradil
significantly reduced TTN 100 µM-induced [Ca++]i rise
down to about 50% of that induced by TTN alone. On the
contrary TTN 100 µM-induced [Ca++]i rise was affected
neither by the L-type Ca++ channel blockers nifedipine
and verapamil nor by the N-type Ca++ channel blocker ω-
Effect of TTN on [Ca++]i in human PMNs Figure 1
Effect of TTN on [Ca++]i in human PMNs. Panel A: Repre-
sentative tracings showing the effect of TTN 100 µM (added 
at arrow) on [Ca++]i in FURA-2-loaded cells under standard 
conditions (left) and after 60-s incubation with PMA 100 ng/
ml (center) or α-PMA 100 ng/ml (right). Panel B: Concen-
tration-response relationship for the effect of PMA (empty 
circles) and lack of effect of α-PMA (empty square) on TTN 
100 µM-induced [Ca++]i rise. Data are expressed as percent-
age of the effect of TTN alone (filled circle). Each point is the 
mean ± SD of 3 separate experiments.
Concentration-response relationship for the effect of rott- lerin (right panel, empty circles) and lack of effect of Ro 32- 0432 (central panel, empty squares) on TTN 100 µM- induced [Ca++]i rise Figure 2
Concentration-response relationship for the effect of rott-
lerin (right panel, empty circles) and lack of effect of Ro 32-
0432 (central panel, empty squares) on TTN 100 µM-
induced [Ca++]i rise. Data are expressed as percentage of the 
effect of TTN alone (left panel, filled circle). Each point is the 
mean ± SD of 3 separate experiments.
Table 2: Effect of rottlerin and of Ro 32-0432 on PMA-dependent 
inhibition of the [Ca++]i rise induced by TTN. Data are expressed 
as percentage of the effect of TTN alone, and are shown as the 
mean ± SD of at least 3 separate experiments. * = P < 0.05, ** = P 
< 0.01 vs TTN alone; # = P < 0.01 vs TTN + PMA.
TTN 100 µM 100.0 ± 15.5
TTN 100 µM + PMA 1 ng/ml 29.3 ± 15.5**
TTN 100 µM + PMA 1 ng/ml
+ rottlerin 3 µM 25.0 ± 18.3**
+ rottlerin 5 µM 47.4 ± 15.1*
+ rottlerin 10 µM 61.5 ± 14.2*
TTN 100 µM + PMA 1 ng/ml
+ Ro 32-0432 5 nM 60.0 ± 13.2**
+ Ro 32-0432 20 nM 89.5 ± 14.7#
+ Ro 32-0432 50 nM 102.3 ± 15.1#Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/6
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conotoxin GVIA (Fig. 3). None of the Ca++ channel block-
ers had any effect per se on [Ca++]i at the concentrations
used in this study (data not shown).
Northern blot analysis provided evidence for the expres-
sion of the mRNA for all the α1 subunits of T-type Ca++
channels (namely, α1G, α1H, and α1I) in human PMNs
(Fig. 4).
Discussion
The endozepine TTN behaves as a chemoattractant factor
for human PMNs, resulting in a typical pattern of cell acti-
vation, which includes a rise of [Ca++]i, with subsequent
IL-8 mRNA expression and release of this proinflamma-
tory chemokine, chemotaxis, induction of oxidative
metabolism and phagocytosis [8,9]. In the present study
we have further characterized the pharmacological profile
of the response to TTN by human PMNs, showing that
PKC exerts a complex modulation of TTN-induced [Ca++]i
rise and that TTN-induced Ca++ entry in these cells is sen-
sitive to T-type Ca++ channel blockers. A tentative synopsis
of the experimental evidences obtained so far is given in
Fig. 5, which should also be taken as a reference frame for
the subsequent discussion of the findings of this study.
In our experiments, the PKC activator PMA prevented
both TTN-induced [Ca++]i rise and IL-8 mRNA expression.
Involvement of PKC was confirmed by the low EC50 value
of PMA, by the inactivity of its negative control α-PMA, as
well by the ability of two chemically unrelated PKC inhib-
itors such as Ro 32-0432 and rottlerin to revert this
response. These observations stand for the existence of a
PKC-operated inhibition of TTN-dependent pathways, a
finding in line with the notion that in PMNs activation of
PKC inhibits the signals responsible for mobilization of
[Ca++]i [11]. Interestingly however PMA did not com-
pletely prevent TTN-induced [Ca++]i rise, and a residual
effect of the peptide (around 20% of the maximal effect)
was still evident even in the presence of high concentra-
tions of PMA (see Fig. 1). This is in line with our previous
results showing that the PKC inhibitor calphostin C per se
significantly reduced the effects of TTN in human PMNs,
suggesting that activation of PKC was also part of the sig-
naling process triggered by this peptide in PMNs [9].
PKC consists of a family of at least 12 serine/threonine
kinases, which are currently divided into three main
groups based on their structure and substrate require-
ments, namely: conventional (Ca++-dependent and acti-
vated by both phosphatidylserine [PS] and diacylglycerol
[DAG], represented by α, βI, βII, and γ), novel (Ca++-inde-
pendent and regulated by PS and DAG, represented by δ,
ε, η, and θ), and atypical (Ca++-independent and regu-
lated by PS but not by DAG, represented by ζ and ι/λ)
[12]. Recent studies have investigated the expression and
role of PKC isoforms in human PMNs, showing in these
cells the presence of conventional (βI,  βII, and α,
although in lower amounts), as well as novel (δ) PKC
[13], and that different isoforms subserve distinct
functions: conventional isoforms regulate PMA-stimu-
Effect of different Ca++ channel blockers on TTN-evoked  [Ca++]i rise in human PMNs Figure 3
Effect of different Ca++ channel blockers on TTN-evoked 
[Ca++]i rise in human PMNs. Data are expressed as percent-
age of the effect of TTN alone. Each bar is the mean ± SD of 
4 experiments. * = P < 0.01 vs TTN alone.
Expression of mRNAs for T-type Ca++ channel α1G (lane 1),  α1H (lane 2), and α1I (lane 3) subunits in human PMNs Figure 4
Expression of mRNAs for T-type Ca++ channel α1G (lane 1), 
α1H (lane 2), and α1I (lane 3) subunits in human PMNs. Data 
are from one representative of 3 separate experiments. N, 
negative control (no RNA); M, molecular weight markers.Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/6
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lated cytoskeletal association and activation of NADPH
oxidase, while novel isoforms modulate other responses
that involve cytoskeletal components [14].
In our experiments, we have used the phorbol ester com-
pound PMA, which penetrates the cytoplasmic membrane
to directly bind and activate PKC [15]. PMA however does
not show a high degree of selectivity for PKC isoforms,
thus resulting in activation of all PKC in the cell. In the
present study, we have therefore investigated the ability of
the PKC inhibitors Ro 32-0432 and rottlerin to revert the
effect of PMA on TTN-induced [Ca++]i rise, as well as to
affect per se this response. Rottlerin has been shown to
inhibit PKCδ with some selectivity over other PKC iso-
forms, while Ro 32-0432 is selective for conventional iso-
forms (reviewed in [12]). According to our results, both
drugs resulted in the reversion of PMA-induced inhibition
of TTN-induced [Ca++]i rise (Table 2), however only rott-
lerin also inhibited per se the effect of TTN (Fig. 2). The
EC50 of rottlerin in this regard was 5.77 µM, which is in
good agreement with the reported IC50 for PKCδ (3–6 µM)
[12]. On the contrary, Ro 32-0432 in the 5–50 nM con-
centration range (which has been reported to be selective
for conventional PKC isoforms [12]) had no effect per se
on the response of human PMNs to TTN (Fig. 2). These
findings, together with the observation that at variance
with Ro 32-0432, rottlerin was only partially effective in
reverting the effect of PMA (Table 2), may suggest that dif-
ferent isoforms of the enzyme play distinct roles in mod-
ulating the responses to TTN. While PKCδ seems to
contribute to the rise of [Ca++]i induced by TTN, activation
of conventional PKC isoforms (possibly, βI, βII, and/or α)
may inhibit this response. When all the PKC isoforms
undergo activation, as in the case of treatment with PMA,
inhibition prevails over facilitation. In future studies, this
hypothesis will be tested by investigating the pattern of
activation of different PKC isoforms occurring as a result
of TTN stimulation in human PMNs.
Few evidence exists about the possible contribution of
membrane Ca++ channels to the effects of TTN on [Ca++]i.
In rat astrocytes, TTN increases [Ca++]i  through a
Schematic representation summarizing the putative signaling pathways acted upon by TTN in human PMNs Figure 5
Schematic representation summarizing the putative signaling pathways acted upon by TTN in human PMNs. TTN likely acti-
vates G protein-coupled membrane receptors, which in turn signal to PLC- and PKC-dependent pathways. PKC may exert 
both positive and negative modulation of TTN signaling, eventually depending on the specific isoform involved. Increased 
[Ca++]i then occurs through both Ca++ release from intracellular stores and Ca++ entry, possibly through T-type Ca++ channels. 
The picture is based upon the results of the present as well as of previous studies [8,9].Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/6
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peripheral-type benzodiazepine receptor-mediated open-
ing of Ca++ channels which are sensitive to the L-type
channel blocker nifedipine but not to the T-type channel
blocker mibefradil nor to the N-type channel blocker ω-
conotoxin GVIA [16], while in the frog adrenal gland,
TTN-induced [Ca++]i rise involves the activation of mem-
brane receptors positively coupled to adenylyl cyclase
through a cholera toxin-sensitive G protein, which in turn
results in Ca++ influx which is inhibited by mibefradil but
not by nifedipine or ω-conotoxin GVIA [17]. In our exper-
iments, TTN-evoked [Ca++]i rise was significantly reduced
by mibefradil and also by flunarizine, another T-type Ca++
channel blocker structurally different from mibefradil,
whereas nifedipine, verapamil (another L-type channel
blocker) and ω-conotoxin GVIA had no effect. Interest-
ingly, the effect of TTN on [Ca++]i was not completely
blocked, an evidence consistent with the idea that TTN
increases [Ca++]i through both release from intracellular
stores and entry through the plasma membrane [8].
The sensitivity of TTN-induced [Ca++]i rise to T-type chan-
nel blockers led us to investigate the expression of T-type
Ca++ channels in human PMNs. Molecular studies have
identified at least 3 voltage-gated Ca++ channel α1 subu-
nits which share the biophysical and pharmacological
properties of T-type channels, namely α1G, α1H, and α1I
[18]. In the present study, northern blot analysis provided
evidence for the expression of the mRNA for all these 3 α1
subunits in human PMNs (Fig. 4). We are not aware of
other studies showing the expression of T-type Ca++ chan-
nels in human PMNs, either at the level of mRNA or of the
protein subunits, and the present findings may therefore
represent the first evidence that such channels are
expressed by these cells. Nonetheless, whether true volt-
age-dependent T-type Ca++ channels occur and play a rel-
evant role in human PMNs remains still largely to be
established. Electrophysiological studies of Ca++ influx in
non-excitable cells such as leukocytes, including PMNs,
have provided evidence for the existence of receptor-
mediated, non voltage-operated Ca++ entry in these cells
[19]. Interesting observations however regard the possible
occurrence, at least in lymphocytes, of non-voltage-oper-
ated Ca++ channels, with an amino acid sequence which is
closely related to classical voltage-operated Ca++ channels
(reviewed in [20]). In human PMNs flunarizine has been
shown to inhibit Ca++ entry triggered by fMLP or by the
Ca++ ionophore A23187 [21]. Available data, including
those reported in the present study, seem thus to support
the existence in human PMNs of Ca++ entry mechanisms
which are closely related to T-type Ca++ channels, from
both the structural and the pharmacological point of
view. Such mechanisms are likely to be involved in the
response of human PMNs to TTN, and may represent the
target of T-type channel blockers such as flunarizine and
mibefradil.
In conclusion, the present results together with previous
studies [8,9] suggest that in human PMNs the endozepine
TTN activates G protein-coupled membrane receptors,
resulting in a signaling cascade which comprises PLC and
PKC. This latter enzyme in particular may exert both pos-
itive and negative effects on TTN signaling, possibly
depending on the specific isoform(s) involved. TTN-acti-
vated pathways finally result in increased [Ca++]i, due to
both Ca++ release from intracellular stores and Ca++ entry
possibly through T-type Ca++ channels. [Ca++]i rise then
signals for activation of cell function, including mRNA
expression and release of the chemokine IL-8 (Fig. 5). DBI
is released from nerve terminals and its fragments can be
detected in liquor and peripheral blood [22].
Endozepines such as TTN may therefore contribute to the
central nervous system-immune system cross-talk. In
addition DBI, also called acyl-CoA binding protein, is
widely distributed in many peripheral organs such as gut
and endocrine cells of the pancreatic islets [23,24], liver,
kidney [25], adrenals [26], adipose tissue, heart, muscles
and mammary gland [27] of different species, and in cir-
culating mononuclear cells [28], in red blood cells [29]
and even in neoplastic cell lines [30]. High concentrations
of DBI and/or of its processing products may therefore
occur locally, e.g. as the result of leakage from damaged
cells during tissue injury. DBI-derived peptides may thus
also add to the multiple agents constituting the local
microenvironment in inflamed tissues. Studies are there-
fore warranted to develop TTN-receptor ligands to assess
the relevance of TTN-operated pathways as novel targets
for the pharmacological modulation of PMNs during the
inflammatory process.
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